Dermatology Specialists of Charlotte offers Clinical Trials and Research in Dermatology

We are currently looking for research participants for:

  • Acne (nutritional supplement)
  • Alopecia Areata
  • Atopic Dermatitis
  • Hidradenitis Suppurativa
  • Psoriatic Arthritis

If interested, call the office (704-943-3714) and choose option 6 to speak with our research coordinator. Or email research@dscmd.com for more information.

Dermatology Specialists of Charlotte in partnership with DJL Research Network currently enrolling in the following trials:

Alopecia Areata

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata

  • Participants must be at least 18 years and ≤60 years for males (≤70 years of age for females)
  • Current AA episode of more than 6 months’ duration and hair loss encompassing at least half of the scalp

Atopic Dermatitis

A Randomized, Double-Blind, Placebo-Controlled Efficacy Study of The Neurokinin-1 Receptor Antagonist VLY-686 in Patients With Atopic Dermatitis

Inclusion Criteria:

  • Male and non-pregnant, non-lactating female patients aged 18 – 70 years (inclusive);
  • Diagnosed with atopic dermatitis;
  • Suffering from chronic pruritus;
  • Body Mass Index (BMI) of ≥18 and ≤40 kg/m2

Exclusion Criteria:

  • Chronic pruritus due to condition other than atopic dermatitis (AD);
  • A positive test for drugs of abuse at the screening or evaluation visits;
  • Exposure to any investigational medication in the past 60 days

Hidradenitis Suppurativa

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan in Subjects with Moderate to Severe Hidradenitis Suppurativa

Inclusion Criteria:

  • Aged at least 18 years of age;
  • Clinical diagnosis of HS (Hurley Stage II or III)

Acne Vulgaris

A Randomized, Double Blind, Phase 2, Comparative 16-Week Study of ACCUMAX SUBLINGUAL (Diindolylmethane, DIM + Vitamin A) and Quercetin vs Placebo in Participants with Moderate to Severe Acne Vulgaris

Inclusion Criteria:

  • 18-45 years
  • Moderate-severe acne vulgaris presenting on the face or on the face and the upper trunk and chest

For more information, visit clinicaltrials.gov

If interested in participating in a clinical trial at DSC, email us at research@dscmd.com 

 

 

 

 

160

Rating: 10 out of 10 (from 54 votes)